- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.02. | OKYO Pharma LTD: OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress | 233 | GlobeNewswire (Europe) | LONDON and NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| OKYO PHARMA Aktie jetzt für 0€ handeln | |||||
| 23.02. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 20.02. | Piper Sandler startet Coverage für OKYO Pharma mit 'Overweight'-Rating | 2 | Investing.com Deutsch | ||
| 20.02. | Piper Sandler initiates OKYO Pharma stock with Overweight rating | 1 | Investing.com | ||
| 13.02. | OKYO Pharma kündigt Aktienplatzierung im Wert von 20 Millionen US-Dollar an | 1 | Investing.com Deutsch | ||
| 13.02. | OKYO Pharma prices public offering at $1.85/share to raise up to $20M | 3 | Seeking Alpha | ||
| 13.02. | OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares | 412 | GlobeNewswire (Europe) | LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 12.02. | OKYO Pharma launches underwritten public offering of ordinary shares | 1 | Seeking Alpha | ||
| 12.02. | OKYO Pharma Announces Public Offering of Ordinary Shares | 334 | GlobeNewswire (Europe) | LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 11.02. | OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners | 550 | GlobeNewswire (Europe) | LONDON and NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 10.02. | OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer | 282 | GlobeNewswire (Europe) | Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate, a blockbuster orphan therapy in corneal diseaseDr. Mantelli... ► Artikel lesen | |
| 10.02. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 30.01. | OKYO Pharma präsentiert Studienergebnisse zu Urcosimod auf jährlicher ASCRS-Tagung | 1 | Investing.com Deutsch | ||
| 30.01. | OKYO Pharma to present urcosimod NCP study results at ASCRS meeting | 1 | Investing.com | ||
| 30.01. | OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting | 333 | GlobeNewswire (Europe) | LONDON and NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 30.01. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 29.01. | H.C. Wainwright reiterates Buy rating on OKYO Pharma stock with $7 price target | 1 | Investing.com | ||
| 28.01. | OKYO Pharma meldet erfolgreiches FDA-Treffen zur klinischen Studie mit Urcosimod | - | Investing.com Deutsch | ||
| 28.01. | OKYO Pharma erhält grünes Licht der FDA für entscheidende NCP-Studie | - | Investing.com Deutsch | ||
| 28.01. | OKYO Pharma receives FDA alignment on Phase 2b/3 trial for NCP treatment | 2 | Investing.com |
1 2 3 4 Weiter >>
70 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IDEXX LABORATORIES | 522,80 | -0,27 % | IDEXX Laboratories: Wachstumsstrategie durch Innovation auf Investorenkonferenz vorgestellt | ||
| BIOXCEL THERAPEUTICS | 1,290 | +1,42 % | Why Are BioXcel Therapeutics Shares Down Friday? | ||
| VOYAGER THERAPEUTICS | 3,326 | -0,89 % | Voyager Therapeutics, Inc.: Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia | CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally "undruggable" targets by leveraging biomolecular... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,008 | -21,05 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 3,890 | -3,02 % | ANAVEX LIFE SCIENCES CORP: Stabilität als Signal | ||
| CELLAVISION | 13,880 | -0,72 % | CellaVision: Solid Quarter driven by Strong Performance in Americas | Organic sales growth:Q4, 2025: 12.2% (-7.4)EBITDA margin:Q4, 2025: 33% (33)Oktober 1st - December 31st, 2025Net sales increased by 5.6% (-7.0) to SEK 197 m (187).Sales increased organically by 12.2%... ► Artikel lesen | |
| PRECISION BIOSCIENCES | 3,960 | 0,00 % | Precision BioSciences Raises $7.5M in Funding | ||
| ZYMEWORKS | 20,600 | 0,00 % | Zymeworks Secures $250 Mln Royalty Funding Deal With Royalty Pharma | WASHINGTON (dpa-AFX) - Zymeworks Inc. (ZYME), a clinical-stage biopharmaceutical company, on Monday entered into a $250 million royalty funding agreement with Royalty Pharma plc (RPRX), a buyer... ► Artikel lesen | |
| VTV THERAPEUTICS | 31,400 | +3,97 % | vTv Therapeutics Inc.: vTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health | HIGH POINT, N.C., Dec. 18, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced a Phase 2 clinical study protocol developed in collaboration... ► Artikel lesen | |
| QUOIN PHARMACEUTICALS | 7,380 | +3,94 % | Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome | Confirmation Received from MHLW That QRX003 Qualifies for Both Orphan Drug Designation and Fast Track Regulatory Review Status Quoin Initiating the Establishment of a Japanese Subsidiary to Facilitate... ► Artikel lesen | |
| NEUPHORIA THERAPEUTICS | 4,470 | -3,97 % | Neuphoria Therapeutics, Inc.: Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions | BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies... ► Artikel lesen | |
| PLIANT THERAPEUTICS | 1,150 | 0,00 % | Pliant Therapeutics, Inc.: Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors | One complete response and three partial responses observed in heavily pretreated ICI-secondary refractory patients in high dose cohorts Deep and durable ongoing responses with median time on treatment... ► Artikel lesen | |
| MIRA PHARMACEUTICALS | 1,020 | +2,51 % | MIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2 | Advancing a selective oral NMDA receptor modulator toward Phase 2a in chemotherapy-induced peripheral neuropathy following favorable Phase 1 safety and tolerability findings MIAMI, FLORIDA / ACCESS... ► Artikel lesen | |
| NUVATION BIO | 4,585 | +0,33 % | Nuvation Bio Inc.: Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Successfully started 216 patients on IBTROZI® (taletrectinib) in the fourth quarter of 2025, for a total of 432 new patient starts since launch in the second half... ► Artikel lesen | |
| ONCONETIX | 0,477 | -18,58 % | Onconetix, Inc.: Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement | CINCINNATI, OH & FORT LEE, NJ, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO), a commercial-stage biotechnology company focused on innovative solutions for men's health and oncology... ► Artikel lesen |
OKYO PHARMA LIMITED gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -1,20 % bei einem Aktienkurs von 1,650 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OKYO PHARMA LIMITED finden Sie auf Wallstreet Online.